Nebulization performance and lung biodistribution profile of PRS-220, an inhaled CTGF antagonist for the treatment of IPF

V. Neiens (Hallbergmoos, Germany), M. Pavlidou (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), A. Konitsiotis (Hallbergmoos, Germany), J. Morgenstern (Hallbergmoos, Germany), T. Mosebach (Hallbergmoos, Germany), M. Richter (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), M. Hagner (Hallbergmoos, Germany), J. Wrennall (Chapel Hill, United States), R. Tarran (Chapel Hill, United States), G. Matschiner (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany)

Source: International Congress 2022 – Promising new approaches in idiopathic interstitial pneumonias

Session: Promising new approaches in idiopathic interstitial pneumonias
Session type: Thematic Poster
Number: 1937

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
V. Neiens (Hallbergmoos, Germany), M. Pavlidou (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), T. Jaquin (Hallbergmoos, Germany), E. Hansbauer (Hallbergmoos, Germany), A. Konitsiotis (Hallbergmoos, Germany), J. Morgenstern (Hallbergmoos, Germany), T. Mosebach (Hallbergmoos, Germany), M. Richter (Hallbergmoos, Germany), C. Wurzenberger (Hallbergmoos, Germany), M. Hagner (Hallbergmoos, Germany), J. Wrennall (Chapel Hill, United States), R. Tarran (Chapel Hill, United States), G. Matschiner (Hallbergmoos, Germany), S. Olwill (Hallbergmoos, Germany). Nebulization performance and lung biodistribution profile of PRS-220, an inhaled CTGF antagonist for the treatment of IPF. 1937

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.